Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Govindan

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Blood|May 30, 1998
Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestationsT L Ortel, K D Moore, M A Quinn-Allen, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|April 29, 2006
Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancerZ T Hammoud, K A Kesler, M K Ferguson, et al.
British Journal of Cancer|October 15, 2009
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancerS Novello, G V Scagliotti, R Rosell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 7, 2002
Phase I study of rubitecan and gemcitabine in patients with advanced malignanciesP M Fracasso, J S Rader, R Govindan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 14, 2011
Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US OncologyS I Jalal, H D Riggs, A Melnyk, et al.
ESMO Open|February 17, 2026
Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung)K He, P M Forde, R Govindan, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Blood|May 30, 1998
Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestationsT L Ortel, K D Moore, M A Quinn-Allen, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|April 29, 2006
Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancerZ T Hammoud, K A Kesler, M K Ferguson, et al.
British Journal of Cancer|October 15, 2009
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancerS Novello, G V Scagliotti, R Rosell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 7, 2002
Phase I study of rubitecan and gemcitabine in patients with advanced malignanciesP M Fracasso, J S Rader, R Govindan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 14, 2011
Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US OncologyS I Jalal, H D Riggs, A Melnyk, et al.
ESMO Open|February 17, 2026
Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung)K He, P M Forde, R Govindan, et al.
Pageof 4